Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia

Eur J Dermatol. 2021 Oct 1;31(5):662-664. doi: 10.1684/ejd.2021.4139.

Authors

Takuya Maeda¹, Azusa Hiura¹, Jiro Uehara¹, Rino Toyoshima¹, Tomoe Nakagawa¹, Koji Yoshino¹

Affiliation

¹ Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

PMID: 34642136
DOI: 10.1684/ejd.2021.4139

No abstract available

MeSH terms

Aged
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Female
Humans
Ipilimumab / adverse effects
Ipilimumab / therapeutic use*
Male
Melanoma / drug therapy*
Melanoma / pathology
Middle Aged
Neoplasm Staging
Nivolumab / adverse effects
Nivolumab / therapeutic use*
Retrospective Studies
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology

Substances

Antineoplastic Agents, Immunological
Ipilimumab
Nivolumab